Fri.Jul 04, 2025

article thumbnail

From Fee-for-Service to Value-Based Care: Enhancing Outcomes in Nephrology 

MedCity News

A systemic change from FFS to VBC would represent more than a payment model switch, but rather a holistic transition toward patient-centered healthcare that prioritizes outcomes over activity. The post From Fee-for-Service to Value-Based Care: Enhancing Outcomes in Nephrology appeared first on MedCity News.

article thumbnail

Pharma welcomes EU push to restore life sciences sector

pharmaphorum

European pharma trade group EFPIA has said that a strategy launched by the EU to bolster the region's standing in life sciences is a "step forward.

Pharma 71
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Next drug patent cliff to challenge Big Pharma strategy

European Pharmaceutical Review

Multiple blockbuster drugs set to lose exclusivity, producing one of the pharmaceutical industry’s most financially significant patent cliffs in over a decade, according to GlobalData. Oncology is one of the key therapy areas set to be affected by pricing pressures as drug patents expire. Pharma companies will need to “rethink revenue strategies, pipeline investments, and lifecycle management to safeguard long-term growth”, as a greater number of biosimilars and generic medicines gain market ent

Pharma 52
article thumbnail

AZ claims EU okay for Imfinzi in bladder cancer

pharmaphorum

AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug

52
article thumbnail

State of AI in Sales & Marketing 2025

AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.

article thumbnail

A Novel, Enhanced, and Sustainable Approach to Audit Trail Review

PharmaTech

Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.

Leads 40
article thumbnail

UK pharma has concerns about the new NHS 10-year plan

pharmaphorum

The ABPI is worried about investment in medicines and moves that could limit patient and doctor treatment choice in the NHS 10-year plan

Doctors 52

More Trending

article thumbnail

Jardiance Ad Analysis: A Marketing Fail

World of DTC Marketing

It’s challenging to watch primetime television or stream content without being bombarded with direct-to-consumer (DTC) pharmaceutical ads. But among the growing list of repetitive, cringeworthy, or overproduced commercials, one ad consistently earns the dubious honor of being the most hated : the Jardiance TV spot. 1. The Jarring Jingle That Won’t Die From the opening notes, the ad forces viewers into an upbeat, Broadway-esque musical number.

Marketing 232
article thumbnail

Hospitalized Adults With Community-Acquired Pneumonia Suffer Significant Morbidity Postdischarge

Pharmacy Times

Six months following discharge from the hospital, adults who battled community-acquired pneumonia were at heightened risk of losing the ability to perform activities and experiencing poor quality of life.

40
article thumbnail

Five lessons from biopharma companies’ data transformation journeys

Pharmaceutical Technology

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

article thumbnail

Advanced Solutions for Sustained Delivery of Ocular Therapies

PharmaTech

News All News Bio/Pharma News Publications All Publications PharmTech PharmTech Europe Resources Marketplace ICH Q9 Revision: A Comprehensive Resource on Quality Risk Management Peer-Reviewed Research PharmTech Products Pharma Insights Sponsored Podcasts Sponsored Videos Sponsored eBooks Whitepapers Webcasts Multimedia All Videos Ask the Expert Behind The Headlines Buy, Sell, Hold Drug Digest Videos Drug Solutions Podcast Peer Exchange Sexy Science Tech Talk Conference Conference Coverage Confer

article thumbnail

The Intersection of AI and Sales: Personalization Without Compromise

Speaker: Jesse Hunter and Brynn Chadwick

Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.

article thumbnail

Brii Biosciences and Joincare sign licence agreement for BRII-693

Pharmaceutical Technology

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Media 52
article thumbnail

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Pharmacy Times

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to

article thumbnail

Biocon’s Denosumab biosimilars gain EU marketing authorisation

Pharmaceutical Technology

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

article thumbnail

Elevated Remnant Cholesterol, Lp-PLA2 Linked to Heightened Risk of Composite Adverse Events

Pharmacy Times

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to

article thumbnail

The GTM Intelligence Era: ZoomInfo 2025 Customer Impact Report

ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!

article thumbnail

Modella AI and AstraZeneca link for cancer clinical development

Pharmaceutical Technology

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

article thumbnail

AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer

Pharmaceutical Technology

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

article thumbnail

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Pharma 52